Tag Archives: Sarepta

  1. Speak Up for the Duchenne Community!

    Posted on October 14, 201511:18 pm

      After waiting for a very long time, the Duchenne community now has clarity on the Advisory Committee meetings dates for BioMarin and Sarepta.  BioMarin’s date is November 24, 2015 and Sarepta’s date is January 22, 2016.  Please remember, these dates are tentative until they actually appear on the Federal Registry.  Both of the Ad Read more »

  2. Welcome Dr. Jak Knowles

    Posted on September 16, 20153:46 pm

    We couldn’t be prouder that CureDuchenne has played a critical role in the development of what we hope will be the first-ever pharmaceutical treatments for Duchenne muscular dystrophy. Investments by CureDuchenne in Prosensa (now BioMarin) and Sarepta Therapeutics have helped advance two drugs through clinical trials that await FDA approval in the fall of 2015. Read more »

  3. Cure Duchenne Has Funded All Types of Duchenne Research

    Posted on September 23, 20145:15 pm

    CureDuchenne is proud to have supported all types of Duchenne research over the past 10 years. That is why CureDuchenne has been a leader in funding exon skipping, stop codon, rare and duplications mutations, utrophin upregulation as well as anti-fibrotic and anti-inflammatory therapies during the past decade. Click here for full image. CureDuchenne’s focus is Read more »

  4. Sarepta and Prosensa Announcements This Week

    Posted on August 8, 20134:40 pm

    There continues to be good news for the Duchenne community.  We will continue to monitor Duchenne research news and share it with you as it becomes available. Here are three announcements from this week: Sarepta Therapeutics Announces Publication of Eteplirsen Clinical Study Results in the Annals of Neurology Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer Read more »

  5. Drisapersen, Etiplersen, GSK, Prosensa and Sarepta, a Positive Week for Duchenne

    Posted on April 11, 201311:09 pm

    Thanks to GSK, Prosensa and Sarepta and, the landscape is changing for the patients and families that are suffering from Duchenne, a severe muscle disease that shortens the life expectancy and quality of life for approximately 300,000 boys and young men worldwide. Even though these potential treatments that are currently in the news have not Read more »

  6. CureDuchenne – Clinical Trials – FDA

    Posted on December 7, 201212:45 am

    Following the long awaited news of Sarepta’s phase IIB results for eteplirsen and continued Phase III progress of GSK/Prosensa’s drisapersen, as well as the recent developments with PTC Therapeutics and Summit PLC among others, CureDuchenne took the initiative to reach out for patients and advocacy groups alike to begin a dialogue with the FDA and Read more »